SETD2 and nonpapillary renal cell carcinoma: Subsequently, a series of in vitro and in vivo experiments revealed that LEDGF binds H3R17me2a to regulate purine nucleotide metabolism in SETD2 mutant ccRCC cells, promoting tumor proliferation, and may be an effective therapeutic target.